318 related articles for article (PubMed ID: 31015264)
1. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
Schütte LM; Cnossen MH; van Hest RM; Driessens MHE; Fijnvandraat K; Polinder S; Beckers EAM; Coppens M; Eikenboom J; Laros-van Gorkom BAP; Meijer K; Nieuwenhuizen L; Mauser-Bunschoten EP; Leebeek FWG; Mathôt RAA; Kruip MJHA
BMJ Open; 2019 Apr; 9(4):e022719. PubMed ID: 31015264
[TBL] [Abstract][Full Text] [Related]
2. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
3. Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM; Al Arashi W; de Jager NCB; Cloesmeijer ME; Bukkems LH; Zwaan CM; Leebeek FWG; Mathôt RAA; Cnossen MH;
BMJ Open; 2022 Feb; 12(2):e049493. PubMed ID: 35168962
[TBL] [Abstract][Full Text] [Related]
4. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
van Moort I; Preijers T; Bukkems LH; Hazendonk HCAM; van der Bom JG; Laros-van Gorkom BAP; Beckers EAM; Nieuwenhuizen L; van der Meer FJM; Ypma P; Coppens M; Fijnvandraat K; Schutgens REG; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH;
Lancet Haematol; 2021 Jul; 8(7):e492-e502. PubMed ID: 34171280
[TBL] [Abstract][Full Text] [Related]
5. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients.
Romano LGR; Schütte LM; van Hest RM; Meijer K; Laros-van Gorkom BAP; Nieuwenhuizen L; Eikenboom J; Heubel-Moenen FCJI; Uitslager N; Coppens M; Fijnvandraat K; Driessens MHE; Polinder S; Cnossen MH; Leebeek FWG; Mathôt RAA; Kruip MJHA;
Haemophilia; 2024 Mar; 30(2):355-366. PubMed ID: 38343113
[TBL] [Abstract][Full Text] [Related]
6. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.
Schütte LM; van Hest RM; Stoof SCM; Leebeek FWG; Cnossen MH; Kruip MJHA; Mathôt RAA
Thromb Haemost; 2018 Apr; 118(4):621-629. PubMed ID: 29458233
[TBL] [Abstract][Full Text] [Related]
8. Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial.
Mansouritorghabeh H; Shirdel A
J Thromb Haemost; 2016 Feb; 14(2):336-9. PubMed ID: 26599105
[TBL] [Abstract][Full Text] [Related]
9. Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen.
Stoof SCM; Schütte LM; Leebeek FWG; Cnossen MH; Kruip MJHA
Haemophilia; 2017 Nov; 23(6):861-867. PubMed ID: 28636264
[TBL] [Abstract][Full Text] [Related]
10. The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?
Schütte LM; Hodes LS; van Moort I; Stoof SCM; Leebeek FWG; Cnossen MH; de Maat MPM; Kruip MJHA
Haemophilia; 2020 Sep; 26(5):916-922. PubMed ID: 32713129
[TBL] [Abstract][Full Text] [Related]
11. Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target.
Schütte LM; de Rooij N; Hazendonk HCAM; Mathôt RAA; van Hest RM; Leebeek FWG; Cnossen MH; Kruip MJHA
Haemophilia; 2019 Nov; 25(6):960-968. PubMed ID: 31487098
[TBL] [Abstract][Full Text] [Related]
12. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
13. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
van Moort I; Bukkems LH; Heijdra JM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Ypma P; de Maat MPM; Leebeek FWG; Meijer K; Eikenboom J; Mathôt RAA; Cnossen MH;
Thromb Haemost; 2020 Jul; 120(7):1056-1065. PubMed ID: 32480417
[TBL] [Abstract][Full Text] [Related]
15. Desmopressin in non-severe haemophilia A: Test-response and clinical outcomes in a single Canadian centre review.
Hews-Girard J; Rydz N; Lee A; Goodyear MD; Poon MC
Haemophilia; 2018 Sep; 24(5):720-725. PubMed ID: 30004154
[TBL] [Abstract][Full Text] [Related]
16. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
Delavenne X; Dargaud Y; Ollier E; Négrier C
Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
[TBL] [Abstract][Full Text] [Related]
17. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA
Ther Drug Monit; 2019 Apr; 41(2):192-212. PubMed ID: 30883513
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
20. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
